 |
PDBsum entry 3f3t
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Chem Biol
5:394-396
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
A new screening assay for allosteric inhibitors of cSrc.
|
|
J.R.Simard,
S.Klüter,
C.Grütter,
M.Getlik,
M.Rabiller,
H.B.Rode,
D.Rauh.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Targeting kinases outside the highly conserved ATP pocket is thought to be a
promising strategy for overcoming bottlenecks in kinase inhibitor research, such
as limited selectivity and drug resistance. Here we report the development and
application of a direct binding assay to detect small molecules that stabilize
the inactive conformation of the tyrosine kinase cSrc. Protein X-ray
crystallography validated the assay results and confirmed an exclusively
allosteric binding mode.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
(a) Structural model of a protein kinase of interest with the
DFG motif (orange) and activation loop (red) highlighted. A
cysteine was mutated into the activation loop of cSrc for
subsequent labeling with the environmentally sensitive
fluorophore acrylodan to generate a sensitive DFG-out
fluorescence-based binding assay. The DFG-out conformation is
stabilized by the binding of allosteric type III inhibitors
(blue surface representation) or type II inhibitors that lock
the kinase in the inactive state. The binding of ATP or type I
inhibitors (yellow surface representation) stabilizes the active
DFG-in conformation. Both conformations are in equilibrium and
result from structural changes in the activation loop and the
DFG motif. (b) Examples of type I, type II and type III kinase
inhibitors and scaffolds. (c) In the absence of ligand,
acrylodan-labeled cSrc shows two emission maxima at 475 nm and
505 nm. Type I ligands induce a robust loss of fluorescence
intensity (represented by red arrows) at 475 nm, resulting in a
red shift in the emission maxima to 510
nm (right panel). Type II and III inhibitors stabilize the
inactive kinase conformation and elicit a different response in
which the emissions at 475 nm and 505 nm are equally reduced
(left panel). The emission signal at 445 nm is less sensitive to
ligand binding and serves as an internal reference point,
allowing for more stable ratiometric fluorescence measurements
and K[d] determinations.
|
 |
Figure 3.
(a) cSrc in complex with the type III inhibitor 1b. (b) cSrc
in complex with the type III inhibitor 1c. Electron density maps
(2F[o] – F[c]) of cSrc (gray) and 1b, 1c (red) are contoured
at 1 .
Hydrogen bonding interactions of the inhibitor with helix C
(blue) and the backbone of the DFG motif (orange) stabilize the
inhibitor in the allosteric site and are highlighted by dotted
lines (red). The hinge region (pink) of the kinase domain
(represented by Met341) is not contacted by either inhibitor.
(c) Alignment of the cSrc–1c complex with BIRB-796 bound to
p38 (yellow)
(Protein Data Bank code 1KV2). Hydrogen bonds of the p38 –BIRB-796
complex are highlighted by dotted lines (red). The pyrazolourea
moiety of both ligands resides in the allosteric site, and the
naphthyl side chain is located in the hydrophobic subpocket
close to the gatekeeper residue (Thr106 in p38 and
Thr338 in cSrc). The morpholino group of BIRB-796 binds to the
hinge region of p38 .
Although the binding mode of the aryl pyrazolourea scaffold is
conserved in both complexes, BIRB-796 binds only weakly to cSrc
with a K[d] > 10 M.
Coordinates and structure factors have been deposited under the
following Protein Data Bank accession codes: cSrc bound to 1b,
3F3U; cSrc bound to 1c, 3F3T.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Chem Biol
(2009,
5,
394-396)
copyright 2009.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
R.Eglen,
and
T.Reisine
(2011).
Drug discovery and the human kinome: recent trends.
|
| |
Pharmacol Ther,
130,
144-156.
|
 |
|
|
|
|
 |
V.V.Vintonyak,
H.Waldmann,
and
D.Rauh
(2011).
Using small molecules to target protein phosphatases.
|
| |
Bioorg Med Chem,
19,
2145-2155.
|
 |
|
|
|
|
 |
D.Falck,
J.S.de Vlieger,
W.M.Niessen,
J.Kool,
M.Honing,
M.Giera,
and
H.Irth
(2010).
Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC-HR-MS.
|
| |
Anal Bioanal Chem,
398,
1771-1780.
|
 |
|
|
|
|
 |
G.S.Loving,
M.Sainlos,
and
B.Imperiali
(2010).
Monitoring protein interactions and dynamics with solvatochromic fluorophores.
|
| |
Trends Biotechnol,
28,
73-83.
|
 |
|
|
|
|
 |
M.Rabiller,
M.Getlik,
S.Klüter,
A.Richters,
S.Tückmantel,
J.R.Simard,
and
D.Rauh
(2010).
Proteus in the world of proteins: conformational changes in protein kinases.
|
| |
Arch Pharm (Weinheim),
343,
193-206.
|
 |
|
|
|
|
 |
P.Ranjitkar,
A.M.Brock,
and
D.J.Maly
(2010).
Affinity reagents that target a specific inactive form of protein kinases.
|
| |
Chem Biol,
17,
195-206.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |